{
    "clinical_study": {
        "@rank": "119544", 
        "brief_summary": {
            "textblock": "Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr\n      infusion of immunotoxin in a Phase I study to determine dose limiting toxicity evidence of\n      response."
        }, 
        "brief_title": "A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma", 
        "completion_date": "April 2001", 
        "condition": "B Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr\n      infusion of immunotoxin in a Phase I study to determine dose limiting toxicity evidence of\n      response."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients with a histologic diagnosis confirmed from a pretreatment biopsy at the\n        Laboratory of Pathology, NCI of one of the following entities:  Diffuse small Lymphocytic\n        Lymphoma;  Follicular, Small Cleaved  cell Lymphoma;  Follicular, Mixed Small Cleaved and\n        Large Cell Lymphoma;  Follicular Large Cell Lymphoma;  Diffuse, Intermediately\n        Differentiated Lymphocytic Lymphoma;  Diffuse, Small Cleaved Cell Lymphoma;  Diffuse,\n        Mixed Small and Large Cell Lymphoma;  Diffuse, Large Cell Lymphoma;  Large Cell\n        Immunoblastic Lymphoma;  Small Noncleaved Cell Lymphoma.\n\n        Presence of CD22 antigen on at least 30 percent of tumor cells.\n\n        Presence of objectively measurable sites of disease.  Bone marrow positivity and\n        circulating tumor cells in the peripheral blood will be considered evaluable but not\n        measurable disease.\n\n        No patients with purely B-cell Lymphosarcoma cell leukemia  without nodal or soft tissue\n        involvement.\n\n        No patients with B-cell chronic lymphocytic leukemia, or B-cell or pre-B-cell acute\n        lymphocytic leukemia, and hairy cell leukemia.\n\n        Patients with objectively measurable disease outside a radiation port or disease which has\n        clearly progressed within a radiation port.\n\n        HIV negative.\n\n        No CNS disease.\n\n        No pulmonary parenchymal disease.\n\n        Pleural effusions or ascites may be present.\n\n        Patients with progression of disease despite at least one standard combination\n        chemotherapy regimen.\n\n        No chemotherapy for at least two weeks prior to entry.\n\n        Patients who do not desire or are not candidates for autologous or allogeneic bone marrow\n        transplantation procedures.\n\n        Life expectancy of at least 3 months\n\n        Creatinine clearance greater than 60 cc per minute.\n\n        Total bilirubin less than 1.5 mg/dl.\n\n        SGPT less than 2 times the upper limit of normal.\n\n        Albumin greater than 75 percent of the lower limit of normal.\n\n        If prior treatment with doxorubicin, the radionuclide or echocardiogram ejection fraction\n        shall be at least 35 percent.\n\n        Performance status 0-2.\n\n        Not in need of current radiation therapy to alleviate local problems.\n\n        No prior exposure to murine antibodies.\n\n        No need for current corticosteroid treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "24", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001271", 
            "org_study_id": "910176", 
            "secondary_id": "91-C-0176"
        }, 
        "intervention": {
            "intervention_name": "IgG-RFB4-SMPT-dgA", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Immunotoxins"
        }, 
        "keyword": [
            "Antigen Modulation", 
            "Pharmacokinetics", 
            "Ricin A Chain"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "3317828", 
                "citation": "Vitetta ES, Fulton RJ, May RD, Till M, Uhr JW. Redesigning nature's poisons to create anti-tumor reagents. Science. 1987 Nov 20;238(4830):1098-104. Review."
            }, 
            {
                "PMID": "2982609", 
                "citation": "Thorpe PE, Detre SI, Foxwell BM, Brown AN, Skilleter DN, Wilson G, Forrester JA, Stirpe F. Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. Eur J Biochem. 1985 Feb 15;147(1):197-206."
            }, 
            {
                "PMID": "3263328", 
                "citation": "Shen GL, Li JL, Ghetie MA, Ghetie V, May RD, Till M, Brown AN, Relf M, Knowles P, Uhr JW, et al. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int J Cancer. 1988 Nov 15;42(5):792-7."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001271"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "July 1991", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2000"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}